The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Cytori Therapeutics Inc

Nasdaq: CYTX
Last

(U.S.) $0.44

Today's change-0.67 -60.60%
Updated July 24 10:49 AM -4GMT. Delayed by at least 15 minutes.
 

Cytori Therapeutics Inc

Nasdaq: CYTX
Last

(U.S.) $0.44

Today's change-0.67 -60.60%
Updated July 24 10:49 AM -4GMT. Delayed by at least 15 minutes.

Cytori Therapeutics Inc crosses below 50-day moving average

Cytori Therapeutics Inc is sharply lower today, dropping (U.S.)$0.67 or 60.60% to (U.S.)$0.44 and crossing below its 50-day moving average. Over the last five days, shares have lost 61.64% and are down 71.04% for the last year to date. This security has underperformed the S&P 500 by 91.95% during the last year.

Key company metrics

  • Open(U.S.) $0.50
  • Previous close(U.S.) $1.11
  • High(U.S.) $0.54
  • Low(U.S.) $0.41
  • Bid / Ask(U.S.) $0.44 / (U.S.) $0.44
  • YTD % change-71.04%
  • Volume3,512,356
  • Average volume (10-day)716,755
  • Average volume (1-month)691,337
  • Average volume (3-month)798,020
  • 52-week range(U.S.) $0.41 to (U.S.) $2.29
  • Beta3.04
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.27
Updated July 24 10:49 AM -4GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-240.81%

Cytori Therapeutics Inc has a net profit margin of -240.81%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.36%Sector:HealthcareIndustry:Medical Equipment, Supplies & Distribution
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue2333
Total other revenue--------
Total revenue2333
Gross profit1222
Total cost of revenue1111
Total operating expense9779
Selling / general / administrative3333
Research & development3345
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)2000
Other operating expenses, total--------
Operating income-7-4-5-6
Interest income (expense), net non-operating-1-1-1-1
Gain (loss) on sale of assets--000
Other--------
Income before tax-8-5-5-6
Income after tax-8-5-5-6
Income tax, total--------
Net income-8-5-5-6
Total adjustments to net income--000
Net income before extra. items-8-5-5-6
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-8-5-5-6
Inc. avail. to common incl. extra. items-8-5-5-6
Diluted net income-8-5-5-6
Dilution adjustment--------
Diluted weighted average shares23212015
Diluted EPS excluding extraordinary itemsvalue per share-0.33-0.24-0.26-0.43
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.26-0.24-0.26-0.43